Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Eva Ulrike Graefe"'
Publikováno v:
Arzneimittelforschung. 52:89-96
According to the European Pharmacopeia a photometric assay is used for the estimation of procyanidins in Crataegi fructus . This assay is also most commonly used for procyanidin analysis in herbal medicinal products (HMPs) containing extracts of hawt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3121bde6cce0580acdfd5763774621
https://doi.org/10.1055/s-0031-1299862
https://doi.org/10.1055/s-0031-1299862
Autor:
Eva Ulrike Graefe-Mody, Hans-Juergen Woerle, Regina Sennewald, Arne Ring, Christian Friedrich, Tobias Brand
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 36:17-24
The aim of this study was to investigate whether multiple doses of the oral and highly selective dipeptidyl peptidase-4 inhibitor linagliptin affect the steady-state pharmacokinetics of the P-glycoprotein substrate digoxin. This single-center, open-l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8628b0a9dafe46a6c35ad0d5fcfc6df2
https://doi.org/10.1007/s13318-011-0028-y
https://doi.org/10.1007/s13318-011-0028-y
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 48:652-661
Objective: Co-administration of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) with pioglitazone may improve glycemic control in patients with Type 2 diabetes due to their complementary mechanisms of action. This study aimed to investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781da44aa337c7abe0d801ee0f01f09e
https://doi.org/10.5414/cpp48652
https://doi.org/10.5414/cpp48652
Autor:
Judith Leitner, Karin Rathgen, Florian B. Mayr, Francesco Cardona, Uwe Schühly, Christa Firbas, Bernd Jilma, Eva Ulrike Graefe-Mody, Alexander O. Spiel, Hildegard Stähle
Publikováno v:
Clinical Pharmacology & Therapeutics. 81:858-866
BIBT986 is a dual inhibitor of factors Xa and IIa. The aim of this study was to compare with placebo the effect of three doses of BIBT986 on coagulation, platelet activation, and inflammation. This was a prospective, randomized, double-blind, placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7b9769f822ada31b83d9fce8a91474
https://doi.org/10.1038/sj.clpt.6100153
https://doi.org/10.1038/sj.clpt.6100153
Autor:
Gisela Jacobasch, Markus Veit, Bernd Drewelow, Bernhard Uehleke, Eva Ulrike Graefe, Joerg Wittig, Hartmut Derendorf, Silke C. Mueller, Anne-Kathrin Riethling, Holger Pforte
Publikováno v:
The Journal of Clinical Pharmacology. 41:492-499
Due to its potentially beneficial impact on human health, the polyphenol quercetin has come into the focus of medicinal interest. However, data on the bioavailability of quercetin after oral intake are scarce and contradictory. Previous investigation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba26eb3a75da8ffa190b700810af76df
https://doi.org/10.1177/00912700122010366
https://doi.org/10.1177/00912700122010366
Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
Autor:
B. Withopf, Hans-Juergen Woerle, Arne Ring, Joachim Stangier, Mario Iovino, Tobias Brand, Eva Ulrike Graefe-Mody
Publikováno v:
International journal of clinical pharmacology and therapeutics. 49(5)
Objective To investigate the effect of the estimated highest therapeutic dose of linagliptin (5 mg) on the pharmacokinetics and pharmacodynamics of warfarin, a CYP2C9 substrate. Subjects and methods This open-label, 2-period, fixed-sequence trial enr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae8c153f9647c4a35cda05d7a118e052
https://pubmed.ncbi.nlm.nih.gov/21543033
https://pubmed.ncbi.nlm.nih.gov/21543033
Publikováno v:
Journal of chromatography. B, Biomedical sciences and applications. 753(2)
After intake of food or herbal medicinal products containing quercetin glycosides, the systemic availability of the genuine glycoside, as well as the systemic occurrence of the aglycone or conjugates of this polyphenol has been a matter of dispute. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12db598937228c1e711ec3d7e18d44e2
https://pubmed.ncbi.nlm.nih.gov/11334336
https://pubmed.ncbi.nlm.nih.gov/11334336
Autor:
Karin Rathgen, Judith Leitner, Florian B. Mayr, Uwe Schuehly, Francesco Cardona, Christa Firbas, Eva Ulrike Graefe-Mody, Bernd Jilma, Hildegard Staehle
Publikováno v:
ResearcherID
Background: BIBT 986 is a novel potent anticoagulant that dually inhibits Factors Xa and IIa. We hypothesized that BIBT 986 would dose-dependently decrease endotoxin-induced, tissue factor triggered coagulation activation. Hence it was the aim of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6900277909b8983237882f8889de163
https://doi.org/10.1182/blood.v108.11.912.912
https://doi.org/10.1182/blood.v108.11.912.912